SERINC2 Protein Drives Cancer Cell Spread to the Brain

SERINC2 Protein Driver Identified in Brain Metastasis Pathogenesis

Researchers at the Duke School of Medicine identified a key mechanism that helps cancer cells spread to the brain, pointing toward a potential new target for future therapies. Brain metastases rank among the most difficult complications of cancer care, frequently resulting in poor clinical outcomes and restricted treatment options for patients diagnosed with advanced disease.

Key Clinical Takeaways:

• The protein SERINC2 drives cancer cell migration and brain invasion by accumulating phosphatidylserine within specialized cellular protrusions.
• This lipid remodeling activates AXL signaling, which regulates tumor motility and interaction with brain immune cells.
• Lowering SERINC2 levels reduced cancer cell invasiveness and slowed brain tumor growth in animal models.

SERINC2 Protein Drives Cancer Cell Invasion in Brain

Published September 22, 2026, in the journal Cell Reports, the study investigates how tumor cells acquire the capacity to migrate, invade surrounding tissue, and establish secondary growths inside the brain. The research team focused on SERINC2 as a critical driver of this invasive cascade. Laboratory findings demonstrate that the protein promotes the accumulation of phosphatidylserine, a specific cell membrane lipid, inside specialized cellular extensions utilized by cancer cells for locomotion.

This localized accumulation triggers the activation of AXL, a signaling protein known to govern cancer cell motility and metastatic behavior. Beyond direct cell movement, the study uncovers an additional function for SERINC2 in shaping the tumor microenvironment. By facilitating the accumulation and release of phosphatidylserine, the protein allows cancer cells to communicate directly with resident brain immune cells, altering their behavior to foster tumor progression.

Experimental Validation in Animal Models

To test the functional relevance of these pathways, the researchers manipulated SERINC2 expression levels in laboratory models. Lowering the amount of SERINC2 rendered the cancer cells significantly less invasive. This reduction also slowed brain tumor growth in animal models.

These findings provide important new insights into the biological mechanisms that drive brain metastasis, said Mikhail Nikiforov, PhD, professor of pathology.

By identifying SERINC2 as a key regulator of both cancer cell invasion and interactions with the brain microenvironment, this work highlights a potential new therapeutic target for slowing or preventing metastatic disease, Nikiforov added.

Translational Research Goals at Duke

The published data reinforce the institutional commitment of the Duke School of Medicine toward translational research designed to inform upcoming treatments for patients battling advanced cancer. While the investigation deepens the scientific understanding of how malignancies interact with surrounding tissue, the clinical timeline requires further validation.

The study establishes a foundational framework for future drug development efforts focused on inhibiting SERINC2 and related signaling cascades.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.